Toronto Dominion Bank Has $2.15 Million Stock Position in Avantor, Inc. (NYSE:AVTR)

Toronto Dominion Bank lifted its stake in Avantor, Inc. (NYSE:AVTR) by 29.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 83,064 shares of the company’s stock after purchasing an additional 18,800 shares during the period. Toronto Dominion Bank’s holdings in Avantor were worth $2,149,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. SG Americas Securities LLC boosted its stake in Avantor by 222.0% during the 2nd quarter. SG Americas Securities LLC now owns 19,996 shares of the company’s stock worth $424,000 after acquiring an additional 13,786 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Avantor by 2.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 26,921 shares of the company’s stock worth $571,000 after purchasing an additional 733 shares in the last quarter. Swedbank AB grew its holdings in shares of Avantor by 1.3% in the 2nd quarter. Swedbank AB now owns 107,182 shares of the company’s stock valued at $2,272,000 after buying an additional 1,327 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Avantor by 403.4% in the 2nd quarter. Assenagon Asset Management S.A. now owns 133,515 shares of the company’s stock valued at $2,831,000 after buying an additional 106,992 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in Avantor by 1,830.3% during the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after buying an additional 1,391 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AVTR has been the subject of a number of research analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 target price on shares of Avantor in a research note on Thursday, September 26th. Barclays decreased their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Robert W. Baird dropped their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. Wells Fargo & Company cut their price target on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, October 28th. Finally, UBS Group dropped their price objective on shares of Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, October 8th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, Avantor presently has an average rating of “Moderate Buy” and a consensus price target of $27.69.

Avantor Stock Down 0.9 %

AVTR opened at $22.33 on Monday. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. The stock’s fifty day simple moving average is $22.47 and its 200 day simple moving average is $23.53. Avantor, Inc. has a 1-year low of $19.59 and a 1-year high of $28.00. The stock has a market cap of $15.20 billion, a PE ratio of 48.54, a price-to-earnings-growth ratio of 2.75 and a beta of 1.29.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.